Tarsus Pharmaceuticals, Inc.
TARS
Kedudukan dalam Saham
#4648
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Harga Saham
$70.79
Modal Pasaran
$3.31B
Perubahan (1 hari)
1.86%
Perubahan (1 tahun)
-0.56%
Negara
US
Perdagangan Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Pendapatan untuk Tarsus Pharmaceuticals, Inc. (TARS)
Pendapatan pada Jun 2026 TTM: $-44.05M
Menurut laporan kewangan terkini Tarsus Pharmaceuticals, Inc., pendapatan semasa syarikat ialah $-44.05M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-135.89M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-62.10M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Tarsus Pharmaceuticals, Inc. dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-44.05M | -61.88% |
| 2024 | $-115.55M | -14.97% |
| 2023 | $-135.89M | 118.85% |
| 2022 | $-62.10M | 350.88% |
| 2021 | $-13.77M | -48.63% |
| 2020 | $-26.81M | 474.21% |
| 2019 | $-4.67M | 254.25% |
| 2018 | $-1.32M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -12,073.99% |
US
|
|
| $-3.09B | 6,907.47% |
US
|
|
| $-4.02B | 9,016.74% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -4,527.96% |
NL
|
